Eisenbach Christoph, Freyse Anne, Lupu Catalin M, Weigand Kilian, Ernst Evelyn, Hoyler Birgit, Stremmel Wolfgang, Bugert Joachim J, Encke Jens
University of Heidelberg, Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxications, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
Vaccine. 2006 Jun 12;24(24):5140-8. doi: 10.1016/j.vaccine.2006.04.013. Epub 2006 May 2.
Surrogate infections with HCV-recombinant vaccinia viruses (HCV-rVV) are a standard method to test the efficacy of hepatitis C virus (HCV) vaccine candidates in the mouse model. We established a panel of 16 HCV-rVV expressing the nonstructural protein 3 (NS3) of HCV genotypes 1a, 1b, 2, 3 and 4. Mice immunized with recombinant NS3 protein derived from HCV genotype 1b were challenged with the rVV. rVV-titers decreased up to 54-fold after subtype 1b challenge and up to 8.5-fold after subtype 1a challenge. No change was detected for genotype 2, 3, or 4. Our model is a convenient and reliable tool to analyze the induction of cross-genotype immunity by experimental vaccination of mice.
用丙型肝炎病毒重组痘苗病毒（HCV-rVV）进行替代感染是在小鼠模型中测试丙型肝炎病毒（HCV）候选疫苗效力的标准方法。我们构建了一组16种HCV-rVV，它们表达HCV 1a、1b、2、3和4型的非结构蛋白3（NS3）。用源自HCV 1b型的重组NS3蛋白免疫的小鼠用rVV进行攻击。1b亚型攻击后rVV滴度下降高达54倍，1a亚型攻击后下降高达8.5倍。2、3或4型未检测到变化。我们的模型是通过对小鼠进行实验性疫苗接种来分析交叉基因型免疫诱导的便捷可靠工具。
